Vivia Biotech can
AML drug profiling
processes thanks to
our access to
from real patients.
Vivia Biotech has access to primary samples from patients diagnosed with a variety of hematological malignancies including AML and can provide extremely valuable data making the difference in your drug development pipeline.
We have specific assays to cover the different mechanisms of action of many drugs and compounds and to capture
the effects of apoptosis, necrosis, cell cycle arrest, proliferation, immune cell modulation, or antibody-dependent
cellular cytotoxicity, between others, directly on patient samples.
Our key innovations supply sound pharmacology using real AML patient samples.
Vivia as Your Companion Diagnostic Clinical Trial in AML
We have developed a precision medicine (PM) ex vivo test with 92% patients predicted to be sensitive and 75% overall survival at 3 years with a backbone first line treatment in AML patients
Using this PM ex vivo test we have analyzed a novel Otsuka drug as CDx clinical trial
A biomarker-driven design was used in a phase Ib clinical trial for the upfront identification and enrollment of AML patients based on the highest sensitivity to the Otsuka drug, discarding those hypothetically resistant ones and thus minimizing the likelihood of treatment failures.
Vivia's Peer-Reviewed Published AML Data
As a result of the complete scientific support we offer to help our clients achieve their goals in AML drugs and compounds, we have collaborated in scientific articles and abstracts with several clients including Bristol-Myers Squibb, Otsuka, Acetylon, Molecular Partners, Tetraphase, Macrogenics, or Janssen, in addition to our own peer-reviewed published AML data.